Bank of America Securities analyst Tazeen Ahmad maintained a Buy rating on Denali Therapeutics (DNLI – Research Report) today. The company’s ...

Morgan Stanley assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report published on Friday, ...

Proficio Capital Partners LLC acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 25,210 shares of the ...

We recently compiled a list of the Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In. In this article, we ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Denali Therapeutics (DNLI – Research Report), ...

Denali Therapeutics DNLI reported a fourth-quarter 2024 loss of 67 cents per share, narrower than the Zacks Consensus ...

In trading on Monday, shares of Denali Therapeutics Inc (Symbol: DNLI) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $15.745 per share.

Oppenheimer analyst Jay Olson lowered the firm’s price target on Denali Therapeutics (DNLI) to $42 from $50 and keeps an Outperform rating on the shares following quarterly results and after hosting ...

Fintel reports that on February 11, 2025, Deutsche Bank initiated coverage of Denali Therapeutics (NasdaqGS:DNLI) with a Buy recommendation. Analyst Price Forecast Suggests 106.92% Upside As of ...

Three of VB's underlying holdings with notable upside to their analyst target prices are CG Oncology Inc (Symbol: CGON), Denali Therapeutics Inc (Symbol: DNLI), and Biohaven Ltd (Symbol ...